Extent of disease: Patients with 10% or less vitiligo and particularly facial or limited lesions tend to benefit most from ...

At the Winter Clinical Dermatology Meeting, April W. Armstrong, MD, MPH, professor and chief of dermatology at the UCLA ...

Loan success stories, a thriving U21 side and fresh breakthroughs show Sunderland’s academy remains vibrant ...

Marc Goodman Leerink Partners LLC, Research Division. Okay. We're going to get going on our next session. Thanks for joining us. I'm Marc Goodman, one of the biopharma analyst at ...

Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug after two new cancer cases emerged. | Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug ...

Sanofi is betting $1.53 billion on a novel drug from Sino Biopharmaceutical, securing global rights to a first-in-class JAK/ROCK inhibitor that could play a double role in the French pharma’s ...

Abington Heights Sophomore Kale Bonnewell took the polar plunge to support Special Olympics. “I really liked being a part of ...

Nektar Therapeutics (NASDAQ:NKTR) Q4 2025 Earnings Call Transcript March 12, 2026 Nektar Therapeutics beats earnings expectations. Reported EPS is $-1.77756, expectations were $-2.47411. Operator: ...

Shilpa Biologicals and mAbTree Biologics secure US FDA orphan drug designation for breakthrough biologics to treat rare blood cancers: Our Bureau, Bengaluru Friday, March 13, 2026 ...

The biliary tract cancer epidemiology section provides insights into the historical and current biliary tract cancer patient pool and forecasted trends for the leading markets. In 2024, the majority ...

Detailed price information for Disc Medicine Inc (IRON-Q) from The Globe and Mail including charting and trades.

Objective Biologics for systemic lupus erythematosus (SLE) demonstrate variable treatment responses across trials. We evaluated baseline biomarkers as predictors of response to guide personalised ...